know the various vendors strategies in the global veterinary pain management market.

The global veterinary pain management market is expected to grow at a CAGR of 8.54% during the forecast period. Some of the prominent vendors in the global veterinary pain management market include Bayer AG, Boehringer Ingelheim International GmbH, Cadila Healthcare Ltd., Chanelle Pharma Group, Daiichi Sankyo Co. Ltd., Dechra Pharmaceuticals Plc, Elanco Animal Health Inc., Merck & Co. Inc., Norbrook Holdings Ltd., and Zoetis Inc. among others.

Vendors are focusing on strategies such as new product launches to strengthen their market position. For instance, Bayer AG, in August 2019, the European Commission approved Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma. Boehringer Ingelheim International GmbH, in March 2018, the company received the fast track designation from the US FDA for nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease.

Request for: Free Sample Report

Cadila Healthcare Ltd., in October 2019, the company received the final approval from the US FDA to market colesevelam hydrochloride tablets to lower the cholesterol level in people. Daiichi Sankyo Co. Ltd., in October 2019, the company announced the launch of VANFLYTA (quizartinib) in Japan for the treatment of adult patients with relapsed/refractory acute myeloid leukemia. Hence, the increasing number of new product launches is expected to propel the growth of the global veterinary pain management market during the forecast period.